All Photos(1)

Documents

COA/COQ

481411

NF-κB Activation Inhibitor III

Name: NF-κB Activation Inhibitor III
Brand: MM

The NF-κB Activation Inhibitor III, also referenced under CAS 380623-76-7, controls the biological activity of NF-κB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.

Synonym(s):

NF-κB Activation Inhibitor III, 3-Chloro-4-nitro-N-(5-nitro-2-thiazolyl)-benzamide, SM-7368

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₀H₅ClN₄O₅S

CAS Number:

380623-76-7

Molecular Weight:

328.69

MDL number:

MFCD00834007

UNSPSC Code:

12352200

NACRES:

NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

amorphous solid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
protect from light

color

light yellow

solubility

DMSO: 10 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C10H5ClN4O5S/c11-6-3-5(1-2-7(6)14(17)18)9(16)13-10-12-4-8(21-10)15(19)20/h1-4H,(H,12,13,16)

InChI key

XCHLNGBTHLJLFG-UHFFFAOYSA-N

General description

A cell-permeable inhibitor of TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells (complete inhibition at 10 µM). The inhibition of MMP-9 upregulation correlates with a concomitant inhibition of TNF-α-dependent cell invasion. Does not affect TNF-α-induced AP-1 activity. The cellular target appears to be downstream of p38 activation.

A cell-permeable thiazoloamide compound that inhibits TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells (complete inhibition at 10 µM). The inhibition of MMP-9 upregulation correlates with a concomitant inhibition of TNF-α-dependent cell invasion. Does not affect TNF-α-induced AP-1 activity. The cellular target appears to be downstream of p38 activation.

Biochem/physiol Actions

Cell permeable: yes

Effective concentration: 10 µM for complete inhibition of TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells

Primary Target
TNF-α-stimulated NF-κB activation and upregulation of MMP-9

Product does not compete with ATP.

Reversible: no

Packaging

Packaged under inert gas

Warning

Toxicity: Irritant (B)

Other Notes

Lee, H.Y., et al. 2005. Biochem. Biophys. Res. Commun.336, 716.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD-L1 and MHC I in colon cancer cells.

Mohamed Hassan et al.

Oncology letters, 25(1), 41-41 (2023-01-03)

Topoisomerase inhibitors are clinically used to treat various cancer types, including colorectal cancer. These drugs also activate signaling pathways that modulate cell survival and immune cell functions. Immunotherapy is promising for certain tumors, including microsatellite instable colorectal cancer, but not

Shedding of syndecan-4 promotes immune cell recruitment and mitigates cardiac dysfunction after lipopolysaccharide challenge in mice.

Mari E Strand et al.

Journal of molecular and cellular cardiology, 88, 133-144 (2015-10-10)

Inflammation is central to heart failure progression. Innate immune signaling increases expression of the transmembrane proteoglycan syndecan-4 in cardiac myocytes and fibroblasts, followed by shedding of its ectodomain. Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service